Workflow
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
GileadGilead(US:GILD) ZACKSยท2024-10-23 23:05

Company Performance - Gilead Sciences (GILD) closed at $87.23, reflecting a -1.05% change from the previous session, underperforming compared to the S&P 500's daily loss of 0.92% [1] - The stock has increased by 5.22% over the past month, outperforming the Medical sector's loss of 4.16% and the S&P 500's gain of 2.68% [1] - Upcoming earnings report is scheduled for November 6, 2024, with expected earnings of $1.62 per share, indicating a year-over-year decline of 29.26% [1] - Projected revenue for the upcoming quarter is $6.99 billion, reflecting a 0.86% decrease from the same quarter last year [1] Annual Estimates - For the annual period, earnings are anticipated to be $3.76 per share, representing a -44.05% change from the previous year, while revenue is expected to be $27.67 billion, showing a +2.04% increase [2] Analyst Estimates and Valuation - Recent revisions to analyst estimates indicate near-term business trends, with positive revisions suggesting analyst optimism about Gilead's profitability [2] - The Zacks Rank system currently rates Gilead Sciences at 3 (Hold), with a 0.51% decrease in the Zacks Consensus EPS estimate over the last 30 days [3] - Gilead Sciences has a Forward P/E ratio of 23.45, which is higher than the industry average of 22.73 [3] - The company has a PEG ratio of 3.07, compared to the industry average PEG ratio of 2.37 [3] Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [4] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [4]